Catalog No.A2001 Synonyms: MDX-010, BMS-734016

For research use only. Not for use in humans.

Ipilimumab is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.

Size Price Stock Quantity  
USD 957 In stock
USD 2707 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Quality Control

Choose Selective Immunology & Inflammation related Inhibitors

Biological Activity

Description Ipilimumab is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.
CTLA-4 [1]
(Cell-free assay)
In vitro

Ipilimumab, is a fully humanized IgG1k monoclonal antibody produced by recombinant DNA technology in a CHO mammalian cell expression system, binding with high affinity to the extracellular domain of human (and Cynomolgus monkey) CTLA-4, and acting as an inhibitor of its complex functions. This essentially results in T-cell activation and proliferation, and in lymphocyte infiltration leading to tumor cell death. However, the enhancement of T effector cell function, combined with the inhibition of CD4+ Treg and CD8+ suppressive cell types, are considered essential for mediating the full therapeutic effects of ipilimumab[2]. Ipilimumab can improve ATC proliferation, enhance the BiAb-mediated tumor-specific cytotoxicity, and increase cytokine synthesis, while it attenuates Treg activity as shown by decreased level of IL-10 secretion and reduced Treg population[3]. Ipilimumab and nivolumab treatments could collaboratively enhance effector and memory T cell responses without inappropriately activating naive T cells[4].

In vivo Ipilimumab is shown in phase III clinical trials to have a survival benefit in metastatic melanoma that is durable in 10% to 20% of patients. Conceivably, the main adverse effects of ipilimumab are autoimmunein nature[1]. Ipilimumab enhances antitumor immunity by inhibiting immunosuppressive activity of regulatory T cells (Treg)[3].


Cell Research:
+ Expand
  • [3]

  • Cell lines: PBMCs
  • Concentrations: 0, 0.5, 5.0, and 50 μg/mL
  • Incubation Time: 14 days
  • Method:

    Add ipilimumab at the initiation of ATC expansion cultures from healthy donors at various concentrations ranging from 0 to 50 μg/mL. ATC(activated T cells) are harvested on day 14, armed with EGFRBi or CD20Bi, and co-cultured at 25:1 E:T(effector:target) ratio for 18 hours with EGFR positive pancreatic cancer cell line (COLO356/FG) or 4 hours with CD20 positive Burkitt's lymphoma cell line (Daudi) for cytotoxicity assay. BiAb-mediated tumor specific cytotoxicity is measured by 51Cr release assay.

    (Only for Reference)
Animal Research:
+ Expand
  • [4]

  • Animal Models: Purpose-bred cynomolgus monkeys
  • Formulation: Saline
  • Dosages: 3 mg/kg or 10 mg/kg
  • Administration: i.v.
    (Only for Reference)

Product Details

Formulation PBS buffer, pH 7.2
Isotype Human IgG
Source CHO cells
Storage Store at -80°C and avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

Tags: buy Ipilimumab | Ipilimumab supplier | purchase Ipilimumab | Ipilimumab cost | Ipilimumab manufacturer | order Ipilimumab | Ipilimumab distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID